1. Home
  2. CRS vs GMAB Comparison

CRS vs GMAB Comparison

Compare CRS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRS
  • GMAB
  • Stock Information
  • Founded
  • CRS 1910
  • GMAB 1999
  • Country
  • CRS United States
  • GMAB Denmark
  • Employees
  • CRS N/A
  • GMAB N/A
  • Industry
  • CRS Steel/Iron Ore
  • GMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRS Industrials
  • GMAB Health Care
  • Exchange
  • CRS Nasdaq
  • GMAB Nasdaq
  • Market Cap
  • CRS 15.4B
  • GMAB 17.4B
  • IPO Year
  • CRS N/A
  • GMAB N/A
  • Fundamental
  • Price
  • CRS $321.36
  • GMAB $31.32
  • Analyst Decision
  • CRS Strong Buy
  • GMAB Strong Buy
  • Analyst Count
  • CRS 5
  • GMAB 6
  • Target Price
  • CRS $374.60
  • GMAB $40.40
  • AVG Volume (30 Days)
  • CRS 731.3K
  • GMAB 1.8M
  • Earning Date
  • CRS 10-23-2025
  • GMAB 11-06-2025
  • Dividend Yield
  • CRS 0.25%
  • GMAB N/A
  • EPS Growth
  • CRS 82.03
  • GMAB 132.41
  • EPS
  • CRS 8.18
  • GMAB 25.10
  • Revenue
  • CRS $2,893,200,000.00
  • GMAB $3,845,670,022.00
  • Revenue This Year
  • CRS $8.82
  • GMAB $24.92
  • Revenue Next Year
  • CRS $9.90
  • GMAB $15.97
  • P/E Ratio
  • CRS $39.27
  • GMAB $1.25
  • Revenue Growth
  • CRS 2.40
  • GMAB 29.57
  • 52 Week Low
  • CRS $138.61
  • GMAB $17.24
  • 52 Week High
  • CRS $342.11
  • GMAB $33.65
  • Technical
  • Relative Strength Index (RSI)
  • CRS 58.20
  • GMAB 63.22
  • Support Level
  • CRS $295.00
  • GMAB $29.98
  • Resistance Level
  • CRS $332.07
  • GMAB $30.82
  • Average True Range (ATR)
  • CRS 14.42
  • GMAB 0.65
  • MACD
  • CRS -3.59
  • GMAB 0.15
  • Stochastic Oscillator
  • CRS 55.89
  • GMAB 94.93

About CRS Carpenter Technology Corporation

Carpenter Technology Corp supplies specialty metals to a variety of end markets, including aerospace and defense, industrial machinery and consumer durables, medical, and energy, among others. The company's reportable segments include; Specialty Alloys Operations and Performance Engineered Products. It generates maximum revenue from the Specialty Alloys Operations segment. The SAO segment is comprised of the company's alloy and stainless steel manufacturing operations. This includes operations performed at mills predominantly in Reading and Latrobe, Pennsylvania, and surrounding areas as well as South Carolina and Alabama. Geographically, the company derives its maximum revenue from the United States and the rest from Europe, Asia Pacific, Mexico, Canada, and other regions.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: